Clinical trials: Healthy Young
Chemotherapy-Induced Nausea and Vomiting
A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)
This study will assess the bioequivalence of a Merck clinical trial formulation of ondansetron compared to a U.S. and non-U.S. marketed formulation of ondansetron.
- Trial name
- NCT00971633
- Testing
- Comparator: Treatment A (Zofran, ondansetron), Comparator: Treatment B (Zofran, ondansetron), Comparator: Treatment C (Zofran, ondansetron)
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Substance-related Disorders, Alcohol-Related Disorders
LaunchPad: Supporting Healthy Decisions and Preventing Drug Use After High School
LaunchPad is an online substance use prevention program for high school seniors. The program is designed to help seniors develop skills and make informed decisions as they transition from high school to young adulthood.
- Conditions
- Substance-related Disorders, Alcohol-Related Disorders, Tobacco Use Disorder, Marijuana Use
- Trial name
- NCT07655609
- Testing
- Introduction, Norms re: Protective Behavior Strategies (PBS), Life Skills
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Prevention Strategies, LLC
Alzheimer's Disease
A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants
This is a first in human Phase 1 study to evaluate the safety, tolerability and pharmacokinetics with healthy young and elderly adult male volunteers after receiving single and multiple ascending dose of BEY2153.
- Trial name
- NCT04476303
- Testing
- BEY2153
- Where
- South Korea
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- BeyondBio Inc.
Acellular Pertussis, Tetanus
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9
The purpose of this study is to evaluate the persistence of antibodies against all the vaccine antigens 1, 3, 5 and 9 years after an initial vaccination with Tdap, and also to assess immunogenicity and safety of another dose of…
- Conditions
- Acellular Pertussis, Tetanus, Diphtheria
- Trial name
- NCT00489970
- Testing
- Taking of blood samples, Boostrix, Adacel
- Where
- 37 sites in United States
- Volunteers
- 1,954 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)
This is a study to evaluate immunogenicity, safety, and tolerability of 2XP HEPTAVAX™-II compared with the 1XP HEPTAVAX™-II in healthy Japanese young adults.
- Trial name
- NCT01463683
- Testing
- 2XP HEPTAVAX™-II SC, 1XP HEPTAVAX™-II SC, 2XP HEPTAVAX™-II IM
- Volunteers
- 722 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Single Ascending Dose Study of Lu AF76432 in Healthy Young Men
The purpose of this study is to investigate safety, tolerability and pharmacokinetics of the drug Lu AF76432 given as single oral ascending doses to healthy young men
- Trial name
- NCT03531229
- Testing
- Lu AF76432
- Where
- United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Healthy
Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered
The purpose of this study is to evaluate the effects of multiple doses of Gemfibrozil on the plasma concentration of a single dose of SAM-531 in healthy young adult subjects and to assess the safety and tolerability of…
- Trial name
- NCT00966966
- Testing
- SAM-531 and gemfibrozil
- Where
- Netherlands
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pain
Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects
The purpose of this study is to investigate the safety and tolerability of AZD2066 using multiple escalating dose panels. There will be separate panels for young healthy volunteers and elderly healthy volunteers.
- Trial name
- NCT00684502
- Testing
- AZD2066
- Where
- Sweden
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Contraception
HR-QoL and Sexuality in Mirena Inserted Contraception Users
The purpose of this study is to evaluate the changes in the quality of life, as well as in the sexual activity, in women inserted with MIRENA, a hormonal contraceptive intra-uterine system, over the first 12 months of use.
- Trial name
- NCT00498784
- Testing
- Mirena
- Where
- France
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
Bioequivalence Study Comparing Two Formulations of Escitalopram
This is a bioequivalence study, which is a regulatory requirement to ensure comparable in vivo performance, i.e. similarities in terms of safety and efficacy, after administration of two different dosage forms of escitalopram.
- Trial name
- NCT01395433
- Testing
- Escitalopram
- Where
- Netherlands
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years., Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80
To Investigate the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Dosing in Healthy Volunteers
AZD2516 is being developed for the oral treatment of chronic neuropathic pain. This study is split in to two parts. Part A will measure the effect of food and a new formulation of the drug in the blood and see how well it is…
- Trial name
- NCT01148095
- Testing
- AZD2516
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Infections, Papillomavirus
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current phase 3b study is designed to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV…
- Trial name
- NCT00552279
- Testing
- Cervarix TM
- Where
- 16 sites in Italy, Romania and 1 more
- Volunteers
- 805 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza (Pandemic)
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2
The purpose of this study is to evaluate the immunogenicity and safety profile of the Avian flu vaccine with and without adjuvant 2 in healthy, young adults. The study is divided down into Parts A1, A2 and B.
- Trial name
- NCT01596725
- Testing
- Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant
- Where
- 5 sites in United States
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- Novavax
Alzheimer's Disease
Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of CHF5074 in young healthy male volunteers.
- Trial name
- CT02 (NCT01203384)
- Testing
- CHF5074 1x, CHF5074 2x, CHF5074 3x
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- CERESPIR
Pharmacokinetics, Pharmacodynamics
A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and Tolerability
This study investigates how ASP3652 is taken up, broken down, and distributed through the body and excreted in individuals of different races.
- Conditions
- Pharmacokinetics, Pharmacodynamics, Healthy Subjects, Effect of Race
- Trial name
- NCT01958047
- Testing
- ASP3652
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Pharmacodynamics
Pharmacodynamic Characterization of Dienogest
This study will be investigated what mechanism of action Dienogest has. The growth of the follicles, the endometrium, the hormones in the blood and the mucus that is produced by the cervix that will be looked upon.
- Trial name
- NCT00754871
- Testing
- Dienogest (81150037), Dienogest (81150231), Dienogest (SH T00660A)
- Where
- Netherlands
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Bayer
Epstein Barr Virus (EBV) Infection
Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults
Phase 1, single-center, randomized, placebo-controlled, double-blind clinical trial. Participants (N = 15) will receive a 2-dose schedule (1 vaccination on day 1 and day 28) randomized, receiving either MVA-BN-EBV (n = 12) or…
- Trial name
- NCT07888088
- Testing
- MVA-BN-EBV
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Healthy Young Children
An Evaluation of the Tolerability and Acceptability of a New Plant-based Formula for Young Children
An evaluation of the tolerability and acceptability of a new plant-based formula in 45 healthy young children
- Trial name
- NCT05265156
- Testing
- Plant based formula for children aged between 12 and 36 months
- Where
- Indonesia
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Nutricia Research
Psoriasis
Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.
Single center, randomized, double-blind, placebo-controlled clinical study to assess the safety and tolerability of PBF-1650 in order to obtain the Maximum Tolerated Dose (MTD).
- Trial name
- ADENOIMMUNE (NCT03798236)
- Testing
- PBF-1650 oral capsules
- Where
- Spain
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Palobiofarma SL
Healthy
A Bioavailability Study Comparing Modified-release Capsules and Immediate Release Capsules in Fed and Fasting Conditions
Part 1: The purpose of this study is to determine the pharmacokinetic profile of 4 different Extended/modified-release formulations and one immediate release formulation of AZD1446.
- Trial name
- NCT01092299
- Testing
- AZD1446
- Where
- 2 sites in Sweden
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- AstraZeneca